Aflibercept in clinical practice; visual acuity, injection numbers and adherence to treatment, for diabetic macular oedema in 21 UK hospitals over 3 years

Journal article

The data showed significant variation between treatment centres for starting age, VA and IMD which influenced adherence and chances of good VA. Once treatment was started IMD did not alter likelihood of improvement. Loading dose intensity did not alter outcome at one year.

Authors: Talks, SJ; Stratton, I; Peto, T; Lotery, A; Chakravarthy, U

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Springer Nature [academic journals on nature.com]
• Journal: Eye
• Volume: 36
• Issue: 1
• Pages: 72-77
• Publication date: 2021-07-09
• DOI: 10.1038/s41433-021-01625-8
• EISSN: 1476-5454
• ISSN: 0950-222X
• Language: English
• Keywords: Internal medicine; Surgery; Cohort; Ophthalmology; Clinical trial; Medicine; Bevacizumab; Aflibercept; Pediatrics; Diabetic retinopathy; Chemotherapy; Diabetes mellitus; Trial registration; Visual acuity; Retrospective cohort study; Dosing